RU2662973C2 - Пептидомиметики - Google Patents

Пептидомиметики Download PDF

Info

Publication number
RU2662973C2
RU2662973C2 RU2015121688A RU2015121688A RU2662973C2 RU 2662973 C2 RU2662973 C2 RU 2662973C2 RU 2015121688 A RU2015121688 A RU 2015121688A RU 2015121688 A RU2015121688 A RU 2015121688A RU 2662973 C2 RU2662973 C2 RU 2662973C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
peptidomimetic
acid sequence
sequence
Prior art date
Application number
RU2015121688A
Other languages
English (en)
Russian (ru)
Other versions
RU2015121688A (ru
Inventor
Никола ВЮЙЁМЬЕ
Сабрина ПАГАНО
Оливер ХАРТЛИ
Хьюберт ГАРТНЕР
ТЕЙКСЕЙРА Присцила КАМИЛЛО
Пол КАТЛЕР
Филипп ФЕРБЕР
Original Assignee
Лез Опито Юниверситер Де Женев
Юниверсите Де Женев
Ф. Хоффманн - Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лез Опито Юниверситер Де Женев, Юниверсите Де Женев, Ф. Хоффманн - Ля Рош Аг filed Critical Лез Опито Юниверситер Де Женев
Publication of RU2015121688A publication Critical patent/RU2015121688A/ru
Application granted granted Critical
Publication of RU2662973C2 publication Critical patent/RU2662973C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
RU2015121688A 2012-11-06 2013-11-06 Пептидомиметики RU2662973C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12191474 2012-11-06
EP12191474.1 2012-11-06
PCT/IB2013/059948 WO2014072916A1 (en) 2012-11-06 2013-11-06 Mimetic peptides

Publications (2)

Publication Number Publication Date
RU2015121688A RU2015121688A (ru) 2016-12-27
RU2662973C2 true RU2662973C2 (ru) 2018-07-31

Family

ID=47115623

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015121688A RU2662973C2 (ru) 2012-11-06 2013-11-06 Пептидомиметики

Country Status (11)

Country Link
US (1) US10087234B2 (enExample)
EP (1) EP2917234B1 (enExample)
JP (1) JP6499967B2 (enExample)
KR (1) KR102215175B1 (enExample)
CN (1) CN104768970B (enExample)
BR (1) BR112015010276A2 (enExample)
CA (1) CA2888657C (enExample)
ES (1) ES2859559T3 (enExample)
MX (1) MX364626B (enExample)
RU (1) RU2662973C2 (enExample)
WO (1) WO2014072916A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018210404B2 (en) * 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
SG11202010016QA (en) * 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
CN108948158B (zh) * 2018-07-21 2021-06-15 河南大学 四连接素模拟肽tnp及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
EA009528B1 (ru) * 2000-08-24 2008-02-28 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид (варианты), содержащая его композиция и лекарственный препарат для профилактики и лечения атеросклероза
WO2012149563A1 (en) * 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
WO2007022248A2 (en) * 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009528B1 (ru) * 2000-08-24 2008-02-28 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид (варианты), содержащая его композиция и лекарственный препарат для профилактики и лечения атеросклероза
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
WO2012149563A1 (en) * 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SVIRIDOV D. et al., Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter, BIOCHEM. & BIOPHYS.RES.COMM., 2011, v. 410, n. 3, p. 446-451. *

Also Published As

Publication number Publication date
WO2014072916A1 (en) 2014-05-15
KR20150082350A (ko) 2015-07-15
MX2015005761A (es) 2015-08-12
US10087234B2 (en) 2018-10-02
CA2888657C (en) 2022-05-03
US20150291682A1 (en) 2015-10-15
ES2859559T3 (es) 2021-10-04
MX364626B (es) 2019-05-03
RU2015121688A (ru) 2016-12-27
JP2016505514A (ja) 2016-02-25
EP2917234A1 (en) 2015-09-16
CN104768970A (zh) 2015-07-08
EP2917234B1 (en) 2020-12-02
CN104768970B (zh) 2019-11-15
KR102215175B1 (ko) 2021-02-15
BR112015010276A2 (pt) 2019-10-15
CA2888657A1 (en) 2014-05-15
JP6499967B2 (ja) 2019-04-10

Similar Documents

Publication Publication Date Title
EP0683234B2 (en) Antibody against beta-amyloid or their derivative and use thereof
US20250123275A1 (en) Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
US20090035874A1 (en) Therapeutic agents and methods for cardiovascular disease
WO2005025616A1 (ja) 抗体の用途
US10087234B2 (en) Mimetic peptides
JP4374316B2 (ja) β−アミロイドまたはその誘導体に対する抗体およびその用途
Fu et al. Characterization of anti‐peptide antibodies directed against an extracellular immunogenic epitope on the human α1‐adrenergic receptor
Ancsin et al. Laminin interactions with the apoproteins of acute-phase HDL: preliminary mapping of the laminin binding site on serum amyloid A
Beaino et al. Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties
KR102025446B1 (ko) 프로필라그린 c 말단 도메인 특이적 항체 및 그의 용도
WO2015021291A2 (en) Antibodies to acetylated cyclophilin and use thereof
WO2004037863A1 (ja) 抗体およびその用途
JP2004159654A (ja) 抗体およびその用途
JP2001069996A (ja) 新規生理活性物質、その製造法および用途